Danicamtiv

Danicamtiv
Clinical data
Other names	MYK-491
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[(1R)-1-[3-(Difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide;
CAS Number	1970972-74-7;
PubChem CID	122424426;
ChemSpider	81367782;
UNII	7B2CS922HI;
KEGG	D11824;
ChEMBL	ChEMBL4594304;
Chemical and physical data
Formula	C16H20F3N5O4S
Molar mass	435.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C;
	InChI InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1; Key:NREKKBAMVWQRES-MRXNPFEDSA-N;

Danicamtiv is a cardiac myosin activator developed by Bristol Myers Squibb to treat dilated cardiomyopathy.^[1]^[2]^[3]^[4]

References

^ Choi, Joohee; Holmes, Joshua B.; Campbell, Kenneth S.; Stelzer, Julian E. (17 October 2023). "Effect of the Novel Myotrope Danicamtiv on Cross-Bridge Behavior in Human Myocardium". Journal of the American Heart Association. 12 (20): e030682. doi:10.1161/JAHA.123.030682. PMC 10757519. PMID 37804193. S2CID 263759444.
^ Shen, Shi; Sewanan, Lorenzo R.; Jacoby, Daniel L.; Campbell, Stuart G. (15 June 2021). "Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium". Journal of the American Heart Association. 10 (12): e020860. doi:10.1161/JAHA.121.020860. PMC 8477869. PMID 34096321.
^ Kooiker, Kristina B.; Mohran, Saffie; Turner, Kyrah L.; Ma, Weikang; Martinson, Amy; Flint, Galina; Qi, Lin; Gao, Chengqian; Zheng, Yahan; McMillen, Timothy S.; Mandrycky, Christian; Mahoney-Schaefer, Max; Freeman, Jeremy C.; Costales Arenas, Elijah Gabriela; Tu, An-Yu; Irving, Thomas C.; Geeves, Michael A.; Tanner, Bertrand C.W.; Regnier, Michael; Davis, Jennifer; Moussavi-Harami, Farid (18 August 2023). "Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle". Circulation Research. 133 (5): 430–443. doi:10.1161/CIRCRESAHA.123.322629. PMC 10434831. PMID 37470183. S2CID 259995078.
^ Grillo, Mark P.; Markova, Svetlana; Evanchik, Marc; Trellu, Marc; Moliner, Patricia; Brun, Priscilla; Perreard-Dumaine, Anne; Vicat, Pascale; Yang, Chun; Driscoll, James P.; Carlson, Tim J. (1 February 2021). "Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy". Xenobiotica. 51 (2): 222–238. doi:10.1080/00498254.2020.1839982. PMID 33078965. S2CID 224812191.

[1] Choi, Joohee; Holmes, Joshua B.; Campbell, Kenneth S.; Stelzer, Julian E. (17 October 2023). "Effect of the Novel Myotrope Danicamtiv on Cross-Bridge Behavior in Human Myocardium". Journal of the American Heart Association. 12 (20): e030682. doi:10.1161/JAHA.123.030682. PMC 10757519. PMID 37804193. S2CID 263759444.

[2] Shen, Shi; Sewanan, Lorenzo R.; Jacoby, Daniel L.; Campbell, Stuart G. (15 June 2021). "Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium". Journal of the American Heart Association. 10 (12): e020860. doi:10.1161/JAHA.121.020860. PMC 8477869. PMID 34096321.

[3] Kooiker, Kristina B.; Mohran, Saffie; Turner, Kyrah L.; Ma, Weikang; Martinson, Amy; Flint, Galina; Qi, Lin; Gao, Chengqian; Zheng, Yahan; McMillen, Timothy S.; Mandrycky, Christian; Mahoney-Schaefer, Max; Freeman, Jeremy C.; Costales Arenas, Elijah Gabriela; Tu, An-Yu; Irving, Thomas C.; Geeves, Michael A.; Tanner, Bertrand C.W.; Regnier, Michael; Davis, Jennifer; Moussavi-Harami, Farid (18 August 2023). "Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle". Circulation Research. 133 (5): 430–443. doi:10.1161/CIRCRESAHA.123.322629. PMC 10434831. PMID 37470183. S2CID 259995078.

[4] Grillo, Mark P.; Markova, Svetlana; Evanchik, Marc; Trellu, Marc; Moliner, Patricia; Brun, Priscilla; Perreard-Dumaine, Anne; Vicat, Pascale; Yang, Chun; Driscoll, James P.; Carlson, Tim J. (1 February 2021). "Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy". Xenobiotica. 51 (2): 222–238. doi:10.1080/00498254.2020.1839982. PMID 33078965. S2CID 224812191.

[1]

[2]

[3]

[4]